the actual benefit of BEROMUN is substantial in the indication "treatment of soft tissue sarcoma of the limbs :
- for subsequent removal of the tumour so as to prevent or delay amputation ;
- in the palliative situation, for irresectable soft tissue sarcoma. "
Clinical Added Value
minor
In view of the available data, the Committee considers that the BEROMUN/melphalan combination provides :
- a minor IAB (level IV) in the treatment of soft tissue sarcoma of the limbs for subsequent removal of the tumour, so as to prevent or delay amputation,
- a minor IAB (level IV) in irresectable soft tissue sarcoma.
Listen
